Compare Revvity Inc (RVTY) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Nuscale Power Corporation — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Nuscale Power Corporation trades at $7.19 (market cap $3.00B). The key difference: Revvity Inc is far larger — about 5.7× Nuscale Power Corporation's market cap, and Revvity Inc pays a 0.18% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Nuscale Power Corporation for 29 Days on average.
| RVTY | SMR | |
|---|---|---|
Market Cap | $16.98B | $3.00B |
Volume | 1,456,900 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $157.36 | $53.43 |
52-Week Low | $82.26 | $7.32 |
Typical Hold Time | 12 Days | 29 Days |
Enterprise Value | $19.30B | $1.93B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
NuScale Power (SMR) trades at $7.20, down 6.13% with bearish technical signals. The company shows concerning fundamentals with negative net income margins (-3,888.7% in 2026) despite analyst consensus of $11.25 price target. Recent news highlights ongoing investor investigations and competitive pressures in the nuclear energy sector.
While analysts maintain 50% buy ratings, significant operational losses and cash burn create substantial risk. The stock faces headwinds from execution challenges and dilution concerns, though long-term nuclear energy adoption trends provide potential upside for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
